Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Recombinant mouse interferon beta|
|Storage buffer||whole serum|
|Storage Conditions||-80° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Neutralization (Neu)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Specificity: Neutralizes mouse interferon beta.
Activity: 1.55x10^6 NU/ml. Interferon was titrated with the use of the cytopathic effect inhibition assay using L929 cells with EMCV, where 2.5 unit/ml of interferon was necessary to produce an endpoint of 50%. One neutralization unit is defined as the amount of serum required to neutralize one unit of mouse IFN beta to an endpoint of 50%.
For retention of full activity, do not store above -70°C.
Type I Interferons (IFN-alpha/beta) are produced primarily in response to viral infection by Natural IFN-producing cells (IPCs) as part of the host immune response and can also inhibit the development of tumors. IFN-beta binding by its receptor results in the activation of the tyrosine kinases Jak1 and Tyk2 and phosphorylation of members of the STAT family of transcription factors, leading to the transcription and expression of the immune response genes. More recently, several members of the toll-like receptor (TLR) family were found to stimulate the production IFN-beta. IFN-beta is currently used clinically for treatment of tumors, infections and multiple sclerosis.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Ifb; IFN-beta; IFNB; Ifnb1